Corinne Betts

Employment

• University of Oxford Post-Doctoral Research Scientist
  2014 - Present
• University of Oxford

Education

• University of Oxford DPhil
  2010 - 2014

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• Dystrophin involvement in peripheral circadian SRF signalling
  Corinne Betts, Aarti Jagannath, Tirsa L.E. van Westering +19 more
  Life Science Alliance 2021 DOI: 10.26508/lsa.202101014
  +Save
• Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
  Human molecular genetics 2019 DOI: 10.1093/hmg/ddy346
  +Save
• Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment.
  Nucleic acid therapeutics 2018 DOI: 10.1089/nat.2018.0747
  +Save
• Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
  PLOS ONE 2018 DOI: 10.1371/journal.pone.0198897
  +Save
• Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.
  EBioMedicine 2018 DOI: 10.1016/j.ebiom.2018.04.024
  +Save
• Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation.
  Human molecular genetics 2016 DOI: 10.1093/hmg/ddw237
  +Save
• Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.
  Scientific reports 2015 DOI: 10.1038/srep17014
  +Save
• Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.
  Scientific reports 2015 DOI: 10.1038/srep11632
  +Save
• Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy.
  Molecules (Basel, Switzerland) 2015 DOI: 10.3390/molecules20058823
  +Save
• How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.
  Human molecular genetics 2015 DOI: 10.1093/hmg/ddv155
  +Save
• Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.
  Scientific reports 2015 DOI: 10.1038/srep08986
  +Save
• Delivery of therapeutic oligonucleotides with cell penetrating peptides.
  Advanced drug delivery reviews 2015 DOI: 10.1016/j.addr.2015.02.008
  +Save
• Detection and quantification of extracellular microRNAs in murine biofluids.
  Biological procedures online 2014 DOI: 10.1186/1480-9222-16-5
  +Save
• Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency.
  Molecular therapy. Nucleic acids 2013 DOI: 10.1038/mtna.2013.51
  +Save
• Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy.
  Current pharmaceutical design 2013 DOI: 10.2174/1381612811319160009
  +Save
• Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.
  Molecular therapy. Nucleic acids 2012 DOI: 10.1038/mtna.2012.26
  +Save
• Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
  Molecular therapy. Nucleic acids 2012 DOI: 10.1038/mtna.2012.30
  +Save
• Optimizing tissue-specific antisense oligonucleotide-peptide conjugates.
  Methods in molecular biology (Clifton, N.J.) 2012 DOI: 10.1007/978-1-61779-767-5_27
  +Save
• Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
  Molecular therapy : the journal of the American Society of Gene Therapy 2011 DOI: 10.1038/mt.2011.79
  +Save
• Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.
  Nature biotechnology 2011 DOI: 10.1038/nbt.1807
  +Save